{
    "clinical_study": {
        "@rank": "4803", 
        "arm_group": {
            "arm_group_label": "Carfilzomib and Dexamethasone", 
            "arm_group_type": "Experimental", 
            "description": "Phase 1: Carfilzomib will be administered at an escalating dose  with dexamethasone administered at 8mg.\nPhase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: Carfilzomib and dexamethasone will be administered in the same fashion as the previous treatment cycles, but only on days 1, 2, 15, and 16."
        }, 
        "brief_summary": {
            "textblock": "This is a Phase 1/2, multicenter, open label, dose-escalation, nonrandomized study to\n      evaluate the safety, pharmacodynamics, and efficacy of a 60-minute infusion of carfilzomib\n      for patients with progressive multiple myeloma."
        }, 
        "brief_title": "Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 1/2, multicenter, open label, dose-escalation, nonrandomized study to\n      evaluate the safety, pharmacodynamics, and efficacy of a 60-minute infusion of carfilzomib\n      for patients with progressive multiple myeloma.\n\n      The study will consist of a screening period, followed by a treatment period of up to eight\n      28-day treatment cycles, followed by a period of maintenance treatment.  Subjects are to be\n      treated until disease progression."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. MM with relapsing or progressive disease at study entry\n\n             a. Defined as progressive MM on patient's last treatment regimen\n\n          2. Measurable disease, as defined by one or more of the following (assessed within 14\n             days prior to first dose):\n\n               1. Serum M-protein \u2265 0.5 g/dL, or\n\n               2. Urine M-protein \u2265 200 mg/24 hours, or\n\n               3. Only in patients who do not meet a or b, then use serum free light chain\n                  (SFLC) > 100 mg/L (involved light chain) and an abnormal kappa/lamda ratio\n\n          3. Age \u2265 18 years\n\n          4. Life expectancy \u2265 6 months\n\n          5. Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2\n\n          6. Adequate hepatic function within 14 days prior to first dose, with bilirubin < 1.5 \u00d7\n             the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine\n             aminotransferase (ALT) < 3 \u00d7 ULN\n\n          7. LVEF \u2265 40%.  2-D transthoracic echocardiogram (ECHO) is the preferred method of\n             evaluation.  Multigated Acquisition Scan (MUGA) is acceptable if ECHO is not\n             available.\n\n          8. Absolute neutrophil count (ANC) \u2265 1000/mm3 within 14 days prior to first dose.\n             Screening ANC is to be independent of granulocyte colony stimulating factor support\n             for \u2265 1 week and pegylated granulocyte colony stimulating factor for \u2265 2 weeks.\n\n          9. Hemoglobin \u2265 8.0 g/dL within 14 days prior to enrollment.  Use of erythropoietic\n             stimulating factors and red blood cell (RBC) transfusions per institutional\n             guidelines is allowed.\n\n         10. Platelet count \u2265 75,000/mm3 (\u2265 50,000/mm^3 if myeloma involvement in the bone marrow\n             is > 50%) within 14 days prior to first dose.  Patients must not have received\n             platelet transfusions for at least 7 days prior to obtaining the screening platelet\n             count\n\n         11. Calculated or measured creatinine clearance (CrCl) of \u2265 15 mL/min within 14 days\n             prior to first dose. Calculation are based on a standard formula, such as the\n             Cockcroft and Gault: [(140 - Age) x Mass (kg) / (72 x Creatinine mg/dL)]; multiply\n             result by 0.85 if female\n\n         12. Written informed consent in accordance with federal, local, and institutional\n             guidelines\n\n         13. Female patients of childbearing potential (FCBP) must have a negative serum pregnancy\n             test within 14 days prior to first dose and agree to use an effective method of\n             contraception during and for 3 months following last dose of drug (more frequent\n             pregnancy tests may be conducted if required per local regulations). Postmenopausal\n             females (> 45 years old and without menses for > 1 year) and surgically sterilized\n             females are exempt from a pregnancy test\n\n         14. Male patients must agree to use an effective barrier method of contraception during\n             study and for 3 months following the last dose if sexually active with a FCBP\n\n        Exclusion Criteria:\n\n          1. Multiple myeloma of IgM subtype\n\n          2. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and\n             skin changes)\n\n          3. Plasma cell leukemia (> 2.0 \u00d7 109/L circulating plasma cells by standard\n             differential)\n\n          4. Waldenstr\u00f6m's macroglobulinemia\n\n          5. Amyloidosis\n\n          6. Glucocorticoid therapy (prednisone > 30 mg/day or equivalent) within 7 days prior to\n             first dose\n\n          7. Cytotoxic chemotherapy with approved or investigational anticancer therapeutics\n             within 28 days prior to first dose\n\n          8. Treatment with bortezomib, thalidomide or lenalidomide within 21 days prior to first\n             dose\n\n          9. Focal radiation therapy within 7 days prior to first dose.  Radiation therapy to an\n             extended field involving a significant volume of bone marrow within 21 days prior to\n             enrollment (i.e., prior radiation must have been to < 30% of the bone marrow)\n\n         10. Immunotherapy within 21 days prior to first dose\n\n         11. Major surgery within 21 days prior to first dose\n\n         12. Active congestive heart failure (New York Heart Association [NYHA] Classes III to\n             IV), symptomatic ischemia, or conduction abnormalities uncontrolled by conventional\n             intervention.  Myocardial infarction within 6 months prior to first dose.\n\n         13. Acute active infection requiring systemic antibiotics, antiviral (except antiviral\n             therapy directed at HBV), or antifungal agents within 14 days prior to first dose\n\n         14. Known human immunodeficiency virus (HIV) seropositivity\n\n         15. Known hepatitis B or C virus infection (except for patients with HBV receiving and\n             responding to HBV antiviral therapy:  these patients are allowed)\n\n         16. Patients with known cirrhosis\n\n         17. Second malignancy within the past 3 years, except:\n\n               1. Adequately treated basal cell or squamous cell skin cancer\n\n               2. Carcinoma in situ of the cervix\n\n               3. Prostate cancer < Gleason score 6 with stable prostate-specific antigen (PSA)\n                  over 12 months\n\n               4. Breast carcinoma in situ with full surgical resection\n\n               5. Treated medullary or papillary thyroid cancer\n\n               6. Patients with myelodysplastic syndrome\n\n         18. Significant neuropathy (Grades 3 to 4) within 14 days prior to first dose\n\n         19. Peripheral neuropathy with pain \u2265 G2 within 14 days prior to first dose\n\n         20. Female patients who are pregnant or lactating\n\n         21. Known history of allergy to Captisol\u00ae (a cyclodextrin derivative used to solubilize\n             carfilzomib)\n\n         22. Prior carfilzomib treatment\n\n         23. Prior participation in any Onyx-sponsored phase 3 trial\n\n         24. Patients with contraindication to dexamethasone\n\n         25. Contraindication to any of the required concomitant drugs or supportive treatments,\n             including hypersensitivity to antiviral drugs, or intolerance to hydration due to\n             preexisting pulmonary or cardiac impairment\n\n         26. Ongoing graft-versus-host disease\n\n         27. Patients with pleural effusions requiring thoracentesis or ascites requiring\n             paracentesis within 14 days prior to enrollment\n\n         28. Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment\n\n         29. Any other clinically significant medical disease or psychiatric condition that, in\n             the Investigator's opinion, may interfere with protocol adherence or a patient's\n             ability to give informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01792102", 
            "org_study_id": "IST-CAR-585"
        }, 
        "intervention": {
            "arm_group_label": "Carfilzomib and Dexamethasone", 
            "description": "Phase 1: Carfilzomib will be administered at an escalating dose by cohort as 60-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle.  On Cycle 1 Days 1 and 2, carfilzomib will be given at 20 mg/m^2.  For all subsequent doses, carfilzomib will be administered at the dose assigned to the cohort (56, 70, or 88 mg/m^2).  Dexamethasone (8 mg IV or PO) will be administered prior to carfilzomib on Days 1, 2, 8, 9, 15, and 16.\nPhase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: From Cycle 9 onward, carfilzomib and dexamethasone will be administered in the same fashion as during the previous treatment cycle, but only on days 1, 2, 15, and 16.", 
            "intervention_name": "Carfilzomib and Dexamethasone", 
            "intervention_type": "Drug", 
            "other_name": "Krypolis\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Multiple Myeloma", 
            "Carfilzomib", 
            "Krypolis", 
            "60 minute infusion"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "rswift@berensononcology.com", 
                    "last_name": "Regina Swift, R.N", 
                    "phone": "310-623-1227"
                }, 
                "facility": {
                    "address": {
                        "city": "West Hollywood", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90069"
                    }, 
                    "name": "James R. Berenson M.D. Inc."
                }, 
                "investigator": {
                    "last_name": "James R Berenson, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lmcbride@hackensackumc.org", 
                    "last_name": "Laura McBride, RN", 
                    "phone": "551-996-8020"
                }, 
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "John Theuer Cancer Center Hackensack University Medical Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Joshua Richter, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "David S Siegel, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1/2 Study of Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Patients With Progressive Multiple Myeloma", 
        "other_outcome": {
            "measure": "Relationship of 60-minute infusion of carflizomib with pharmacodynamic markers", 
            "safety_issue": "No", 
            "time_frame": "weekly for 2 months"
        }, 
        "overall_contact": {
            "email": "cturner@oncotherapeutics.com", 
            "last_name": "Carley E Turner", 
            "phone": "(310) 623-1206"
        }, 
        "overall_contact_backup": {
            "last_name": "Liv Thulin", 
            "phone": "310-623-1200"
        }, 
        "overall_official": [
            {
                "affiliation": "James Berenson Inc.", 
                "last_name": "James Berenson, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "John Theurer Cancer Center at Hackensack University Medical Center", 
                "last_name": "Joshua Richter, M.D", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Maximum tolerated dose will be established by the number of dose limiting toxicities and the overall safety and tolerability of the study drug.\nSafety and tolerability will be determined by the following:\nincidence and frequency of adverse events throughout the study\nclinical laboratory test results at study visits\nvital signs measurements at each study visits\nmedical history and physical examination findings\nECOG performance status at study visits\nconcomitant medication usage throughout the study", 
            "measure": "Establish maximum tolerated dose (MTD)", 
            "safety_issue": "Yes", 
            "time_frame": "monthly, up to 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01792102"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Response rate will be determined by the following:\nSPEP, UPEP, and quantification of immunoglobulins and immunofixation\nbone marrow aspirates and biopsies to confirm CR\nroentgenographic skeletal survey\nResponse rate will be assessed by the following:\nClinical benefit response rate\nProgression-free survival\nTime to progression\nDuration of response\nOverall survival\nPharmacodynamics", 
            "measure": "Establish efficacy as assessed by the overall response rate", 
            "safety_issue": "No", 
            "time_frame": "monthly, up to 24 months"
        }, 
        "source": "Oncotherapeutics", 
        "sponsors": {
            "collaborator": {
                "agency": "Onyx Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Oncotherapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}